# JR3 Mission Files Archive

**Date Archived:** January 28, 2025  
**Status:** ✅ **COMPLETE** - All mission objectives achieved

---

## Files Archived

### Ovarian Cancer Pathway Validation (JR3)
1. `MISSION_JR3_COMPLETE_PATHWAY_RESISTANCE.mdc` - Complete mission plan
2. `MISSION_JR3_DATA_ACQUISITION_STATUS.mdc` - Data acquisition completion report
3. `MISSION_JR3_EXECUTION_PLAN.mdc` - Execution plan and phases
4. `MISSION_JR3_RESULTS_SUMMARY.mdc` - Validation results summary
5. `MISSION_JR3_REVIEW_AND_QUESTIONS.mdc` - Review and Q&A document
6. `MISSION_JR3_STATUS.mdc` - Status updates during execution

### Multiple Myeloma Resistance Prediction (MM)
7. `MISSION_MM_NEXT_ITERATION.mdc` - Complete MM resistance implementation plan
8. `MISSION_MM_NEXT_ITERATION_QUESTIONS.md` - Questions and answers for implementation

---

## Key Takeaways (Integrated into `ayesha_plan.mdc` Section 21)

### Ovarian Cancer Validation Results
- ✅ **3/5 pathways validated** with TCGA-OV cohort (n=469)
- ✅ **MAPK**: RR=1.97 (validated)
- ✅ **PI3K**: RR=1.57 (newly validated)
- ✅ **DDR/HRD**: RR=1.96 (validated with real HRD scores from GISTIC)
- ⚠️ **TP53 GOF**: RR=0.93 (no signal, as expected)
- ⚠️ **ABCB1 Efflux**: RR=1.05 (no significant signal)

### Multiple Myeloma Implementation
- ✅ **DIS3**: RR=2.08, p=0.0145 (SIGNIFICANT)
- ✅ **TP53**: RR=1.90 (trend)
- ✅ **ResistancePlaybookService** - Shared service (OV + MM)
- ✅ **API Endpoint** - `/api/resistance/predict` (disease-agnostic)
- ✅ **Frontend** - `ResistancePanel.jsx` integrated

### SAE Gap Finding
- ⚠️ **SAE infrastructure exists but NOT used in MM validation**
- Current approach uses mutation presence + proxy scores
- Real SAE available but requires Evo2 service with SAE enabled

---

## Reference

All key takeaways have been integrated into:
- `.cursor/plans/ayesha_plan.mdc` - Section 21: Resistance Pathway Validation Results

**Status:** ✅ **ARCHIVED** - Content preserved, integrated into master plan



